Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim ...

Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8.3 months. The ...

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients ...

Imdelltra was linked to a 29% lower risk of disease progression or death compared with chemotherapy. The median progression-free survival time was 4.2 months and 3.7 months, respectively.

IMDELLTRA ® (tarlatamab-dlle) Important Safety Information (USPI) WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME ...

THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA ® (tarlatamab-dlle) reduced ...

Initiate treatment with IMDELLTRA ® using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA ® until CRS resolves or permanently discontinue based on ...

Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.